Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Free Cash Flow (2023 - 2026)

ArriVent BioPharma has reported Free Cash Flow over the past 4 years, most recently at -$41.9 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$41.9 million for Q1 2026, up 38.4% from a year ago — trailing twelve months through Mar 2026 was -$134.5 million (down 12.44% YoY), and the annual figure for FY2025 was -$160.6 million, down 128.72%.
  • Free Cash Flow reached -$41.9 million in Q1 2026 per AVBP's latest filing, down from -$30.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$8.6 million in Q2 2023 and bottomed at -$68.0 million in Q1 2025.
  • Median Free Cash Flow over the past 4 years was -$18.6 million (2024), compared with a mean of -$25.3 million.
  • The largest annual shift saw Free Cash Flow plummeted 265.08% in 2025 before it soared 38.4% in 2026.
  • Over 4 years, Free Cash Flow stood at -$14.9 million in 2023, then dropped by 8.31% to -$16.2 million in 2024, then tumbled by 89.81% to -$30.7 million in 2025, then tumbled by 36.64% to -$41.9 million in 2026.
  • Business Quant data shows Free Cash Flow for AVBP at -$41.9 million in Q1 2026, -$30.7 million in Q4 2025, and -$35.8 million in Q3 2025.